<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380961</url>
  </required_header>
  <id_info>
    <org_study_id>CR108820</org_study_id>
    <secondary_id>CNTO136COV2001</secondary_id>
    <secondary_id>2020-003056-32</secondary_id>
    <nct_id>NCT04380961</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19</brief_title>
  <official_title>Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutica N.V., Belgium</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutica N.V., Belgium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical response of sirukumab (administered as&#xD;
      a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of&#xD;
      coronavirus disease 2019 (COVID-19), is an enveloped, positive-sense, single-stranded&#xD;
      ribonucleic acid (RNA) betacoronavirus. Symptoms of COVID-19 infection may appear from 2 to&#xD;
      14 days following exposure, with the spectrum of illnesses ranging from mild symptoms to&#xD;
      severe illness or death. The identification of SARS-CoV-2 follows the emergence of 2 other&#xD;
      novel betacoronaviruses: SARS-CoV and Middle East respiratory syndrome coronavirus&#xD;
      (MERS-CoV). Current management of COVID-19 is supportive, and respiratory failure from acute&#xD;
      respiratory distress syndrome (ARDS) is the leading cause of mortality. While an&#xD;
      understanding of the epidemiology and clinical spectrum of COVID-19 is still evolving during&#xD;
      the ongoing pandemic, the current knowledge of the disease burden highlights the urgent&#xD;
      medical need to develop a treatment. Sirukumab (also known as CNTO136) is a human&#xD;
      anti-interleukin (IL)-6 immunoglobulin G1 kappa (IgG1k) monoclonal antibody (mAb). Sirukumab&#xD;
      binds with high affinity and specificity to human IL-6 and as a result inhibits IL-6-mediated&#xD;
      signaling and the biological effects of IL-6. The study will include a Screening Phase (up to&#xD;
      1 Day), a Treatment Phase (Day 1 to Day 28) and a Follow-up Phase (post Day 28, follow-up&#xD;
      phone calls on Week 8, Week 12 and Week 16). Safety evaluations will include monitoring of&#xD;
      adverse events and serious adverse events, physical examinations, vital sign measurements,&#xD;
      electrocardiograms, clinical laboratory tests, pregnancy testing, and checking of vital&#xD;
      status. The entire study duration for each participant will be 16 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Actual">June 24, 2021</completion_date>
  <primary_completion_date type="Actual">April 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal Clinical Recovery Scale (CRS): Primary Analysis Set</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to sustained improvement is defined as an improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Improvement of At Least 2 Categories Compared to Baseline on 6-point Ordinal CRS</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of participants with an improvement of at least 2 Categories compared to baseline on 6-point ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All-cause Mortality Up to 28 Days</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Percentage of participants with all-cause mortality up to 28 days were reported. All-cause mortality included all deaths of participants due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal CRS: Intent-to-Treat (ITT) Set</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to sustained improvement is defined as an improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Improvement of at Least 2 Categories Compared to Baseline on 6-point Ordinal CRS: ITT Set</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of participants with an improvement of at least 2 categories compared to baseline on 6-point ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With All-cause Mortality: ITT Set</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of participants with all-cause mortality were reported. All-cause mortality included all deaths of participants due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs) (Treatment Phase)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Percentage of participants with SAEs were reported. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Related Adverse Events (AEs)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Percentage of participants with related AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Severe or Life-threatening, Bacterial, Invasive Fungal, Viral or Opportunistic Infections</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Percentage of participants with severe or Life-threatening, bacterial, invasive fungal, viral or opportunistic infections were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 3 and 4 Neutropenia and Lymphocytopenia</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Percentage of participants with Grade 3 and 4 neutropenia and lymphocytopenia were reported. The laboratory abnormalities were determined as per division of microbiology and infectious diseases (DMID) adult toxicity as Grade 1: mild (transient or mild discomfort [less than {&lt;} 48 hours]; no medical intervention/therapy required); Grade 2: moderate (mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required); Grade 3: severe (severe marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible); Grade 4: life-threatening (extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Increased Alanine Transaminase (ALT) Greater Than or Equal to (&gt;=)3*Upper Limit Normal (ULN) Combined With Increased Bilirubin Greater Than (&gt;)2*ULN</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Percentage of participants with increased ALT &gt;=3*ULN combined with increased bilirubin &gt;2*ULN were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Improvement of at Least 1 Category on 6-point Ordinal CRS: Primary Analysis Set</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to sustained improvement is defined as an improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Improvement of at Least 1 Category on 6-point Ordinal CRS: ITT Set</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to sustained improvement is defined as an improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Improvement of at Least 1 Category Compared to Baseline on 6-point Ordinal CRS: Primary Analysis Set</measure>
    <time_frame>Day 28</time_frame>
    <description>The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6), reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: (category 1) not hospitalized, including participants on low level of oxygen; Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Improvement of at Least 1 Category on 6-point Ordinal CRS: ITT Set</measure>
    <time_frame>Day 28</time_frame>
    <description>The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Study Intervention Administration to End of Oxygen Supplementation</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time from study intervention administration to end of oxygen supplementation was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Study Intervention Administration to Hospital Discharge Among the Surviving Participants</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time from study intervention administration to hospital discharge among the surviving participants was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Length of Hospitalization Among the Surviving Participants</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Total length of hospitalization, defined as total duration of hospital stay, among the surviving participants was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilation Free Days</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Number of ventilation free days in participants on invasive mechanical ventilation (IVM)/extracorporeal membrane oxygenation (ECMO) at baseline was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Status as Assessed by 6-point Ordinal CRS: Primary Analysis Set</measure>
    <time_frame>On Day 7, 14, 21, 28</time_frame>
    <description>Percentage of participants with clinical status as assessed by 6-point Ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: Not hospitalized, not requiring supplemental oxygen (category 1.1); Not hospitalized, requiring supplemental oxygen (category 1.2); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Status as Assessed by 6-point Ordinal CRS: ITT Set</measure>
    <time_frame>On Days 7, 14, 21, 28</time_frame>
    <description>Percentage of participants with clinical status as assessed by 6-point Ordinal CRS (ITT Set) were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: Not hospitalized, not requiring supplemental oxygen (category 1.1); Not hospitalized, requiring supplemental oxygen (category 1.2); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Time on Invasive Mechanical Ventilation</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Total time on invasive mechanical ventilation in participants who were on invasive mechanical ventilation at baseline was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Worse Category Relative to Baseline on the 6-point Ordinal CRS</measure>
    <time_frame>From Day 5 up to Day 28</time_frame>
    <description>Percentage of participants with a worse category relative to baseline on the 6-point ordinal CRS for at least one of the daily assessment during the reporting period Day 5 and Day 28 were reported. he 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Extracorporeal Membrane Oxygenation (ECMO) Over Time</measure>
    <time_frame>From Day 1 up to Day 28</time_frame>
    <description>Percentage of participants with ECMO over time were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Time on ECMO</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Total time for participants on ECMO was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Alive Participants at Day 28, Week 8, and Week 16</measure>
    <time_frame>On Day 28, Week 8 and Week 16</time_frame>
    <description>Percentage of alive participants at Day 28, Week 8, and Week 16 were reported. For this outcome measure, at Week 8, data was not collected for participants due to pandemic situation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Alive Participants That Required Readmission at Week 8, and Week 16</measure>
    <time_frame>Week 8 and Week 16</time_frame>
    <description>Percentage of alive participants that required readmission at Week 8, and Week 16 were reported. For this outcome measure, at Week 8 and Week 16, data was not collected for participants due to pandemic situation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SAEs (Follow-up Phase)</measure>
    <time_frame>From Week 4 up to Week 16</time_frame>
    <description>Percentage of participants with SAEs were reported. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Critical Confirmed Coronavirus Disease (COVID)-19</condition>
  <arm_group>
    <arm_group_label>Sirukumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single intravenously (IV) dose infusion of sirukumab on Day 1 along with standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV single dose infusion of placebo on Day 1 along with standard of care treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirukumab</intervention_name>
    <description>Participants will receive single dose infusion of sirukumab on Day 1.</description>
    <arm_group_label>Sirukumab</arm_group_label>
    <other_name>CNTO136</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo IV single dose infusion on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care (SOC)</intervention_name>
    <description>SOC treatment will be determined by the investigator based on local practice and consists of supportive care.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sirukumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized&#xD;
&#xD;
          -  Has laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             infection as determined by real time-polymerase chain reaction (PCR) at any time&#xD;
             before randomization&#xD;
&#xD;
          -  Evidence of infiltrates by chest X-ray, chest computed tomography (CT), lung&#xD;
             ultrasound, or chest auscultation (rales, crackles)&#xD;
&#xD;
          -  Informed consent must be obtained from the participant indicating that he or she&#xD;
             understands the purpose of, and procedures required for, the study and is willing to&#xD;
             participate in the study&#xD;
&#xD;
          -  Critical COVID-19 disease, defined as: Requires supplemental oxygen delivered by&#xD;
             nonrebreather mask or high-flow nasal cannula or use of non-invasive or invasive&#xD;
             ventilation or requiring treatment in an intensive care unit&#xD;
&#xD;
               1. AND corresponding to category 4 on the 6-point ordinal recovery scale, that is:&#xD;
                  requires one of the above modalities to sustain a peripheral capillary oxygen&#xD;
                  saturation (SpO2) greater than (&gt;) 93 percent (%) with a fraction of inspired&#xD;
                  oxygen (FiO2) of 50% or higher. Note, the use of other devices may fit with&#xD;
                  category 4 if the FiO2 is 50% or higher.&#xD;
&#xD;
               2. OR, corresponding to category 5 on the 6-point ordinal recovery scale, that is&#xD;
                  partial pressure of oxygen in arterial per percentage of inspired oxygen&#xD;
                  (PaO2/FiO2) ratio &lt; 300 millimeter of mercury (mmHg) while on invasive mechanical&#xD;
                  ventilation or veno-venous extracorporeal membrane oxygenation (ECMO) for less&#xD;
                  than 48 hours prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On invasive mechanical ventilation or on veno-venous ECMO for &gt;48 hours at time of&#xD;
             screening&#xD;
&#xD;
          -  Received an investigational intervention (including investigational vaccines) or used&#xD;
             an invasive investigational medical device within 30 days before the planned dose of&#xD;
             study intervention. Note: the investigator must ensure that the participant is not&#xD;
             enrolled in another COVID-19 study with an investigational intervention (apart from&#xD;
             the exception specified below) prior to completion of Day 28 of the current study.&#xD;
             Exception: participation in a single arm study, a non-blinded controlled study,&#xD;
             expanded access, compassionate use program or any other program that is not a blinded&#xD;
             study is allowed if it is conducted with one of the following: agents with&#xD;
             demonstrated in vitro-effect against SARSCoV- 2, as mentioned in the center of disease&#xD;
             control and prevention (CDC) guidelines and convalescent plasma&#xD;
&#xD;
          -  Current confirmed or high suspicion for pulmonary embolus, hemodynamic significant&#xD;
             pericardial effusion, myocarditis, or Class 3 or 4 congestive heart failure as defined&#xD;
             by the New York Heart Association Functional Classification AND/OR Current evidence of&#xD;
             active cardiac ischemia&#xD;
&#xD;
          -  Has a history of respiratory condition (that is, asthma, chronic obstructive pulmonary&#xD;
             disease (COPD), cystic fibrosis, fibrotic lung disease) that requires home oxygen&#xD;
             supplementation, supportive non-invasive ventilation or, is status/post lung volume&#xD;
             reduction surgery (LVRS). Exception: Participants with sleep apnea using supportive&#xD;
             non-invasive ventilation (continuous positive airway pressure [CPAP]) at screening may&#xD;
             be included&#xD;
&#xD;
          -  On renal replacement therapy (defined as peritoneal dialysis or hemodialysis)&#xD;
&#xD;
          -  Screening laboratory test result as follows: absolute neutrophil count (ANC) &lt;1.0*10^3&#xD;
             cells/microliter; Platelet count &lt;50*10^3 cells/microliter; estimated glomerular&#xD;
             filtration rate (eGFR) &lt;=30 milliliter per minute per 1.73 square meter (mL/min/1.73&#xD;
             m^2); Bilirubin &gt;2* upper limit of normal (ULN) unless bilirubin rise is due to&#xD;
             Gilbert's syndrome or of non-hepatic origin; alanine aminotransferase/ aspartate&#xD;
             aminotransferase (ALT) &gt;5*ULN; Prothrombin time (PT)/international normalized ratio&#xD;
             (INR) &gt;1.5*ULN or activated partial thromboplastin time (aPTT) &gt;1.5*ULN related to&#xD;
             known coagulopathy or bleeding disorder (the participant can receive anticoagulant&#xD;
             therapies for underlying conditions, or as systematic thromboprophylaxis due to&#xD;
             COVID-19, or as part of the treatment of complications of COVID-19, but cannot&#xD;
             participate in a clinical study with anticoagulants for COVID-19)&#xD;
&#xD;
          -  Pregnant or breastfeeding, unless in the opinion of the investigator, the benefit&#xD;
             outweighs the risks&#xD;
&#xD;
          -  Has active hepatitis B or C infection or has human immunodeficiency virus infection or&#xD;
             acquired immune deficiency syndrome (HIV/AIDS) based on medical history and/or&#xD;
             concomitant medication&#xD;
&#xD;
          -  Known active or latent tuberculosis (TB), history of incompletely treated TB,&#xD;
             suspected or known extrapulmonary TB based on medical history and/or concomitant&#xD;
             medication&#xD;
&#xD;
          -  Evidence of active bacterial (including but not limited to bacterial pneumonia),&#xD;
             fungal, viral or opportunistic infection (other than SARS-CoV-2)&#xD;
&#xD;
          -  Currently active clinically significant (example, causing hemodynamic instability&#xD;
             and/or causing hypoxemia) and uncontrolled arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutica N.V., Belgium Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutica N.V., Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MemorialCare Research Miller Children's and Women's Hospital Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois College of Medicine at Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Health Systems</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical Group, PLLC</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michaels Medical Center - Infectious Disease</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints Medical Center at Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <results_first_submitted>April 8, 2022</results_first_submitted>
  <results_first_submitted_qc>May 23, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">June 21, 2022</results_first_posted>
  <last_update_submitted>May 23, 2022</last_update_submitted>
  <last_update_submitted_qc>May 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 17, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04380961/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 28, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT04380961/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of 212 participants who started the study and got randomized, 209 participants (139 in Sirukumab + Standard of Care [SOC] and 70 in Placebo + SOC arm) were treated. Out of 212, 139 participants (96 in Sirukumab + SOC and 43 in Placebo + SOC arms) completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sirukumab + SOC</title>
          <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + SOC</title>
          <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Who Entered the Follow-up Phase</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITT) analysis set consisted of all participants who were randomized and treated in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Sirukumab + SOC</title>
          <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + SOC</title>
          <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="139"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="209"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="12.91"/>
                    <measurement group_id="B2" value="57.8" spread="12.91"/>
                    <measurement group_id="B3" value="57.8" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal Clinical Recovery Scale (CRS): Primary Analysis Set</title>
        <description>Time to sustained improvement is defined as an improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The Primary Analysis Set consisted of all participants in the Intent-to-Treat (ITT) analysis set (which consisted of all participants who were randomized and treated in the study) with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal Clinical Recovery Scale (CRS): Primary Analysis Set</title>
          <description>Time to sustained improvement is defined as an improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The Primary Analysis Set consisted of all participants in the Intent-to-Treat (ITT) analysis set (which consisted of all participants who were randomized and treated in the study) with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.00" lower_limit="13.00" upper_limit="NA">NA stands for data Not available as indicates upper limit of 95% CI was not estimable due to less number of events.</measurement>
                    <measurement group_id="O2" value="23.00" lower_limit="13.00" upper_limit="NA">NA stands for data Not available as indicates upper limit of 95% CI was not estimable due to less number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Improvement of At Least 2 Categories Compared to Baseline on 6-point Ordinal CRS</title>
        <description>Percentage of participants with an improvement of at least 2 Categories compared to baseline on 6-point ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>Day 28</time_frame>
        <population>The Primary Analysis Set consisted of all participants in the ITT analysis set with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Improvement of At Least 2 Categories Compared to Baseline on 6-point Ordinal CRS</title>
          <description>Percentage of participants with an improvement of at least 2 Categories compared to baseline on 6-point ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The Primary Analysis Set consisted of all participants in the ITT analysis set with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All-cause Mortality Up to 28 Days</title>
        <description>Percentage of participants with all-cause mortality up to 28 days were reported. All-cause mortality included all deaths of participants due to any cause.</description>
        <time_frame>Up to 28 days</time_frame>
        <population>The Primary Analysis Set consisted of all participants in the ITT analysis set with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All-cause Mortality Up to 28 Days</title>
          <description>Percentage of participants with all-cause mortality up to 28 days were reported. All-cause mortality included all deaths of participants due to any cause.</description>
          <population>The Primary Analysis Set consisted of all participants in the ITT analysis set with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal CRS: Intent-to-Treat (ITT) Set</title>
        <description>Time to sustained improvement is defined as an improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal CRS: Intent-to-Treat (ITT) Set</title>
          <description>Time to sustained improvement is defined as an improvement of at least 2 categories relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="7.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="10.00" lower_limit="8.00" upper_limit="17.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Improvement of at Least 2 Categories Compared to Baseline on 6-point Ordinal CRS: ITT Set</title>
        <description>Percentage of participants with an improvement of at least 2 categories compared to baseline on 6-point ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>Day 28</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. There were 3 participants in the 'Sirukumab + SOC arm' who discontinued the trial before Day 28 and thus were not evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Improvement of at Least 2 Categories Compared to Baseline on 6-point Ordinal CRS: ITT Set</title>
          <description>Percentage of participants with an improvement of at least 2 categories compared to baseline on 6-point ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. There were 3 participants in the 'Sirukumab + SOC arm' who discontinued the trial before Day 28 and thus were not evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With All-cause Mortality: ITT Set</title>
        <description>Percentage of participants with all-cause mortality were reported. All-cause mortality included all deaths of participants due to any cause.</description>
        <time_frame>Day 28</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. There were 3 participants in the 'Sirukumab + SOC arm' who discontinued the trial before Day 28 and thus were not evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With All-cause Mortality: ITT Set</title>
          <description>Percentage of participants with all-cause mortality were reported. All-cause mortality included all deaths of participants due to any cause.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. There were 3 participants in the 'Sirukumab + SOC arm' who discontinued the trial before Day 28 and thus were not evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs) (Treatment Phase)</title>
        <description>Percentage of participants with SAEs were reported. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The All Subjects treated analysis set consisted of all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs) (Treatment Phase)</title>
          <description>Percentage of participants with SAEs were reported. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
          <population>The All Subjects treated analysis set consisted of all participants who received the study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Related Adverse Events (AEs)</title>
        <description>Percentage of participants with related AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The All Subjects Treated analysis set consisted of all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Related Adverse Events (AEs)</title>
          <description>Percentage of participants with related AEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
          <population>The All Subjects Treated analysis set consisted of all participants who received the study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Severe or Life-threatening, Bacterial, Invasive Fungal, Viral or Opportunistic Infections</title>
        <description>Percentage of participants with severe or Life-threatening, bacterial, invasive fungal, viral or opportunistic infections were reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The All Subjects treated analysis set consisted of all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Severe or Life-threatening, Bacterial, Invasive Fungal, Viral or Opportunistic Infections</title>
          <description>Percentage of participants with severe or Life-threatening, bacterial, invasive fungal, viral or opportunistic infections were reported.</description>
          <population>The All Subjects treated analysis set consisted of all participants who received the study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 3 and 4 Neutropenia and Lymphocytopenia</title>
        <description>Percentage of participants with Grade 3 and 4 neutropenia and lymphocytopenia were reported. The laboratory abnormalities were determined as per division of microbiology and infectious diseases (DMID) adult toxicity as Grade 1: mild (transient or mild discomfort [less than {&lt;} 48 hours]; no medical intervention/therapy required); Grade 2: moderate (mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required); Grade 3: severe (severe marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible); Grade 4: life-threatening (extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable).</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The All Subjects Treated analysis set consists of all participants who received the study drug. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. Here, 'n' (number analyzed) is defined as participants analyzed for specified categories.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 3 and 4 Neutropenia and Lymphocytopenia</title>
          <description>Percentage of participants with Grade 3 and 4 neutropenia and lymphocytopenia were reported. The laboratory abnormalities were determined as per division of microbiology and infectious diseases (DMID) adult toxicity as Grade 1: mild (transient or mild discomfort [less than {&lt;} 48 hours]; no medical intervention/therapy required); Grade 2: moderate (mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required); Grade 3: severe (severe marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalizations possible); Grade 4: life-threatening (extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable).</description>
          <population>The All Subjects Treated analysis set consists of all participants who received the study drug. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. Here, 'n' (number analyzed) is defined as participants analyzed for specified categories.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytopenia: Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytopenia: Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Increased Alanine Transaminase (ALT) Greater Than or Equal to (&gt;=)3*Upper Limit Normal (ULN) Combined With Increased Bilirubin Greater Than (&gt;)2*ULN</title>
        <description>Percentage of participants with increased ALT &gt;=3*ULN combined with increased bilirubin &gt;2*ULN were reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The All Subjects Treated analysis set consists of all participants who received the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Increased Alanine Transaminase (ALT) Greater Than or Equal to (&gt;=)3*Upper Limit Normal (ULN) Combined With Increased Bilirubin Greater Than (&gt;)2*ULN</title>
          <description>Percentage of participants with increased ALT &gt;=3*ULN combined with increased bilirubin &gt;2*ULN were reported.</description>
          <population>The All Subjects Treated analysis set consists of all participants who received the study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Sustained Improvement of at Least 1 Category on 6-point Ordinal CRS: Primary Analysis Set</title>
        <description>Time to sustained improvement is defined as an improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The Primary Analysis Set consisted of all participants in the ITT analysis set with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Sustained Improvement of at Least 1 Category on 6-point Ordinal CRS: Primary Analysis Set</title>
          <description>Time to sustained improvement is defined as an improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The Primary Analysis Set consisted of all participants in the ITT analysis set with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" lower_limit="7.00" upper_limit="21.00"/>
                    <measurement group_id="O2" value="15.50" lower_limit="8.00" upper_limit="NA">NA stands for data Not available, indicates upper limit of 90% CI was not estimable due to less number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Sustained Improvement of at Least 1 Category on 6-point Ordinal CRS: ITT Set</title>
        <description>Time to sustained improvement is defined as an improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Sustained Improvement of at Least 1 Category on 6-point Ordinal CRS: ITT Set</title>
          <description>Time to sustained improvement is defined as an improvement of at least 1 category relative to baseline on the 6-point ordinal clinical recovery scale, sustained until Day 28. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="6.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="7.00" lower_limit="6.00" upper_limit="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Improvement of at Least 1 Category Compared to Baseline on 6-point Ordinal CRS: Primary Analysis Set</title>
        <description>The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6), reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: (category 1) not hospitalized, including participants on low level of oxygen; Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>Day 28</time_frame>
        <population>The Primary Analysis Set consisted of all participants in the ITT analysis set with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. There were 3 participants in the 'Sirukumab + SOC arm' who discontinued the trial before Day 28 and thus were not evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Improvement of at Least 1 Category Compared to Baseline on 6-point Ordinal CRS: Primary Analysis Set</title>
          <description>The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6), reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: (category 1) not hospitalized, including participants on low level of oxygen; Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The Primary Analysis Set consisted of all participants in the ITT analysis set with confirmed critical COVID-19 disease defined as score of 4 or 5 on the ordinal CRS at baseline. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. There were 3 participants in the 'Sirukumab + SOC arm' who discontinued the trial before Day 28 and thus were not evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                    <measurement group_id="O2" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Improvement of at Least 1 Category on 6-point Ordinal CRS: ITT Set</title>
        <description>The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening</description>
        <time_frame>Day 28</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. There were 3 participants in the 'Sirukumab + SOC arm' who discontinued the trial before Day 28 and thus were not evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Improvement of at Least 1 Category on 6-point Ordinal CRS: ITT Set</title>
          <description>The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure. There were 3 participants in the 'Sirukumab + SOC arm' who discontinued the trial before Day 28 and thus were not evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1"/>
                    <measurement group_id="O2" value="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Study Intervention Administration to End of Oxygen Supplementation</title>
        <description>Time from study intervention administration to end of oxygen supplementation was reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Study Intervention Administration to End of Oxygen Supplementation</title>
          <description>Time from study intervention administration to end of oxygen supplementation was reported.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="10.00" upper_limit="NA">NA indicates data not available as upper limit of 90% CI was not estimable due to less number of events.</measurement>
                    <measurement group_id="O2" value="20.00" lower_limit="9.00" upper_limit="NA">NA indicates data not available as upper limit of 90% CI was not estimable due to less number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Study Intervention Administration to Hospital Discharge Among the Surviving Participants</title>
        <description>Time from study intervention administration to hospital discharge among the surviving participants was reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The ITT population restricted to participants surviving up to Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Study Intervention Administration to Hospital Discharge Among the Surviving Participants</title>
          <description>Time from study intervention administration to hospital discharge among the surviving participants was reported.</description>
          <population>The ITT population restricted to participants surviving up to Day 28.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="7.00" upper_limit="9.00"/>
                    <measurement group_id="O2" value="9.00" lower_limit="7.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Length of Hospitalization Among the Surviving Participants</title>
        <description>Total length of hospitalization, defined as total duration of hospital stay, among the surviving participants was reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The ITT population restricted to participants surviving up to Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Length of Hospitalization Among the Surviving Participants</title>
          <description>Total length of hospitalization, defined as total duration of hospital stay, among the surviving participants was reported.</description>
          <population>The ITT population restricted to participants surviving up to Day 28.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.42" spread="8.274"/>
                    <measurement group_id="O2" value="11.19" spread="8.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ventilation Free Days</title>
        <description>Number of ventilation free days in participants on invasive mechanical ventilation (IVM)/extracorporeal membrane oxygenation (ECMO) at baseline was reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The Primary Analysis Set restricted to participants who were on IVM/ECMO at baseline. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ventilation Free Days</title>
          <description>Number of ventilation free days in participants on invasive mechanical ventilation (IVM)/extracorporeal membrane oxygenation (ECMO) at baseline was reported.</description>
          <population>The Primary Analysis Set restricted to participants who were on IVM/ECMO at baseline. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.82" spread="11.062"/>
                    <measurement group_id="O2" value="6.63" spread="9.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Status as Assessed by 6-point Ordinal CRS: Primary Analysis Set</title>
        <description>Percentage of participants with clinical status as assessed by 6-point Ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: Not hospitalized, not requiring supplemental oxygen (category 1.1); Not hospitalized, requiring supplemental oxygen (category 1.2); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>On Day 7, 14, 21, 28</time_frame>
        <population>The Primary Analysis Set consisted of all participants in the ITT set with confirmed critical COVID-19 disease defined as score of 4 or 5 on ordinal CRS at baseline. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure. Here, 'n' (number analyzed) is defined as participants analyzed for specified categories at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Status as Assessed by 6-point Ordinal CRS: Primary Analysis Set</title>
          <description>Percentage of participants with clinical status as assessed by 6-point Ordinal CRS were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: Not hospitalized, not requiring supplemental oxygen (category 1.1); Not hospitalized, requiring supplemental oxygen (category 1.2); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The Primary Analysis Set consisted of all participants in the ITT set with confirmed critical COVID-19 disease defined as score of 4 or 5 on ordinal CRS at baseline. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure. Here, 'n' (number analyzed) is defined as participants analyzed for specified categories at specified timepoints.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7: Category 1.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 1.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                    <measurement group_id="O2" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 1.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 1.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 1.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 1.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 1.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 1.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Status as Assessed by 6-point Ordinal CRS: ITT Set</title>
        <description>Percentage of participants with clinical status as assessed by 6-point Ordinal CRS (ITT Set) were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: Not hospitalized, not requiring supplemental oxygen (category 1.1); Not hospitalized, requiring supplemental oxygen (category 1.2); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>On Days 7, 14, 21, 28</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure. Here, 'n' (number analyzed) is defined as participants analyzed for specified categories at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Status as Assessed by 6-point Ordinal CRS: ITT Set</title>
          <description>Percentage of participants with clinical status as assessed by 6-point Ordinal CRS (ITT Set) were reported. The 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: Not hospitalized, not requiring supplemental oxygen (category 1.1); Not hospitalized, requiring supplemental oxygen (category 1.2); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure. Here, 'n' (number analyzed) is defined as participants analyzed for specified categories at specified timepoints.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7: Category 1.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 1.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7: Category 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 1.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 1.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14: Category 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 1.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6"/>
                    <measurement group_id="O2" value="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 1.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21: Category 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 1.1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 1.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Category 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Time on Invasive Mechanical Ventilation</title>
        <description>Total time on invasive mechanical ventilation in participants who were on invasive mechanical ventilation at baseline was reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The Primary Analysis Set restricted to participants who were on invasive mechanical ventilation at baseline. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Time on Invasive Mechanical Ventilation</title>
          <description>Total time on invasive mechanical ventilation in participants who were on invasive mechanical ventilation at baseline was reported.</description>
          <population>The Primary Analysis Set restricted to participants who were on invasive mechanical ventilation at baseline. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.18" spread="11.062"/>
                    <measurement group_id="O2" value="21.37" spread="9.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Worse Category Relative to Baseline on the 6-point Ordinal CRS</title>
        <description>Percentage of participants with a worse category relative to baseline on the 6-point ordinal CRS for at least one of the daily assessment during the reporting period Day 5 and Day 28 were reported. he 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
        <time_frame>From Day 5 up to Day 28</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Worse Category Relative to Baseline on the 6-point Ordinal CRS</title>
          <description>Percentage of participants with a worse category relative to baseline on the 6-point ordinal CRS for at least one of the daily assessment during the reporting period Day 5 and Day 28 were reported. he 6-point ordinal CRS provides 6 mutually exclusive conditions ordered from best (score 1) to worst (score 6) corresponding to below categories, reflects the participant's worst situation on the day assessed. The ordinal clinical recovery scale categories are: not hospitalized, including participants on low level of oxygen (category 1); Hospitalization, not requiring supplemental oxygen (category 2); hospitalized, requiring low flow supplemental oxygen (category 3); hospitalized, on non-invasive pressure ventilation or high flow oxygen devices (category 4); hospitalized, on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) (category 5); death (category 6). Higher scores indicated greater worsening.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Extracorporeal Membrane Oxygenation (ECMO) Over Time</title>
        <description>Percentage of participants with ECMO over time were reported.</description>
        <time_frame>From Day 1 up to Day 28</time_frame>
        <population>The ITT population restricted to participants who were on ECMO at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Extracorporeal Membrane Oxygenation (ECMO) Over Time</title>
          <description>Percentage of participants with ECMO over time were reported.</description>
          <population>The ITT population restricted to participants who were on ECMO at baseline.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Time on ECMO</title>
        <description>Total time for participants on ECMO was reported.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>The ITT set restricted to participants who were on ECMO at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Time on ECMO</title>
          <description>Total time for participants on ECMO was reported.</description>
          <population>The ITT set restricted to participants who were on ECMO at baseline.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0"/>
                    <measurement group_id="O2" value="1.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Alive Participants at Day 28, Week 8, and Week 16</title>
        <description>Percentage of alive participants at Day 28, Week 8, and Week 16 were reported. For this outcome measure, at Week 8, data was not collected for participants due to pandemic situation.</description>
        <time_frame>On Day 28, Week 8 and Week 16</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure. Here, 'n' (number analyzed) is defined as participants analyzed for specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Alive Participants at Day 28, Week 8, and Week 16</title>
          <description>Percentage of alive participants at Day 28, Week 8, and Week 16 were reported. For this outcome measure, at Week 8, data was not collected for participants due to pandemic situation.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study. Here 'N' (number of participants analyzed) included all participants evaluable for this outcome measure. Here, 'n' (number analyzed) is defined as participants analyzed for specified timepoints.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3"/>
                    <measurement group_id="O2" value="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Alive Participants That Required Readmission at Week 8, and Week 16</title>
        <description>Percentage of alive participants that required readmission at Week 8, and Week 16 were reported. For this outcome measure, at Week 8 and Week 16, data was not collected for participants due to pandemic situation.</description>
        <time_frame>Week 8 and Week 16</time_frame>
        <population>The ITT analysis set consisted of all participants who were randomized and treated in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Alive Participants That Required Readmission at Week 8, and Week 16</title>
          <description>Percentage of alive participants that required readmission at Week 8, and Week 16 were reported. For this outcome measure, at Week 8 and Week 16, data was not collected for participants due to pandemic situation.</description>
          <population>The ITT analysis set consisted of all participants who were randomized and treated in the study.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SAEs (Follow-up Phase)</title>
        <description>Percentage of participants with SAEs were reported. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>From Week 4 up to Week 16</time_frame>
        <population>The All Subjects Treated analysis set consists of all participants who received the study drug. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirukumab + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with standard of care (SOC) treatment per the discretion of the Investigator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + SOC</title>
            <description>Hospitalized participants with confirmed severe or critical COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SAEs (Follow-up Phase)</title>
          <description>Percentage of participants with SAEs were reported. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
          <population>The All Subjects Treated analysis set consists of all participants who received the study drug. Here, 'N' (Number of participants analyzed) included all participants evaluable for this outcome measure.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment phase: Weeks 0-4; Follow-up phase: Weeks 4-16</time_frame>
      <desc>The All Subjects Treated analysis set consisted of all participants who received the study drug. The number of participants at risk in placebo arm in follow-up phase were 59 participants, however, the data for 2 participants in placebo arms were not collected due to pandemic situation, and were excluded from the analysis. Therefore, here number of participants at risk are 57 participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sirukumab + Standard of Care (SOC): Treatment Phase</title>
          <description>Hospitalized participants with confirmed coronavirus disease-2019 (COVID-19) received intravenous (IV) single dose infusion of sirukumab (5 milligrams per kilogram [mg/kg]) on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
        </group>
        <group group_id="E2">
          <title>Sirukumab + SOC: Follow-up Phase</title>
          <description>Hospitalized participants with confirmed COVID-19 received IV single dose infusion of sirukumab 5 mg/kg on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
        </group>
        <group group_id="E3">
          <title>Placebo + SOC: Treatment Phase</title>
          <description>Hospitalized participants with confirmed COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
        </group>
        <group group_id="E4">
          <title>Placebo + SOC: Follow-up Phase</title>
          <description>Hospitalized participants with confirmed COVID-19 disease received IV single dose infusion of placebo on Day 1 along with SOC treatment per the discretion of the Investigator.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Blood Loss Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Mouth Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Organ Dysfunction Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Covid-19</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Covid-19 Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Enterobacter Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Enterococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hiv Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Klebsiella Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Staphylococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Streptococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Viral Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration Rate Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Urine Analysis Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Embolic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumothorax Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Haemodialysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Troponin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director 1 Study Responsible Physician</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

